Teaching the body to manufacture “designer” antibodies from a tiny pool of edited stem cells could turn today’s short‑lived antibody infusions into a one‑time treatment that can be boosted for years.
Image by Magnific
Antibody drugs play a critical role in treating chronic infections, cancer and other persistent diseases, but their effects are short-lived. Patients require repeated infusions to maintain protection. A recent study introduces an alternative: rather than administering antibodies repeatedly, this method enables the body to produce its own supply for extended periods.
The study, published in the journal Science, edited a small number of blood-forming cells in mice so that the immune cells those cells produce carry a blueprint for a chosen antibody. Once placed in the body, the edited cells grow into a living antibody factory that responds to a simple vaccine booster.
Antibodies are proteins produced by the immune system to recognize and bind to harmful targets, including viruses and cancer cells. Pharmaceutical manufacturers produce these antibodies in controlled environments, purify them and administer them to patients. However, the body eliminates these antibodies within weeks, requiring patients to receive repeated doses to maintain therapeutic levels.
The cost adds up fast. A single year of antibody treatment can run into tens of thousands of dollars. Some of the most useful antibodies, the rare kind that can block many different versions of a virus like HIV or the flu, are even harder to make and even harder to keep at the right level in the blood.
This approach begins with blood-forming stem cells found in the bone marrow. These cells generate all red blood cells and immune cells throughout life, providing a continuous source for the body's cellular components.
MORE FOR YOU
Gene editing inserts the genetic code for a selected antibody into a specific region of these stem cells, targeting the area responsible for antibody production. After transplantation into mice, the edited stem cells differentiate into antibody-producing white blood cells, each programmed to generate the chosen antibody.
The setup is quiet until the body needs it. When the mouse gets a vaccine that matches the chosen antibody, those edited immune cells spring into action. They multiply, mature and start pumping out the antibody at high levels. A booster shot can ramp up supply at any time. Only about 7,000 edited stem cells were needed to create useful antibody levels. That is far fewer than the millions of cells used in some other gene therapies.
The approach was tested against three of the most stubborn infections in medicine. In mice carrying the gene recipe for an HIV-blocking antibody, blood levels stayed high enough to stop the virus from infecting cells in lab tests. In mice loaded with an antibody against malaria, the malaria parasite could no longer slip into the liver. In mice given a flu-fighting antibody, each survived a deadly dose of a flu strain different from the one used to make the antibody. All the mice receiving no treatment died.
Administering two populations of edited stem cells enables the simultaneous production of two distinct antibodies. This strategy is important for rapidly evolving viruses such as HIV, as targeting multiple viral variants reduces the likelihood of escape.
In a separate test, human blood-forming stem cells were edited in the lab. They were then placed in mice with weakened immune systems. The cells grew into human immune cells that produced the chosen antibody. This suggests the approach has a real chance of working in people, although human trials are still years away.
The platform can also be adapted to produce proteins unrelated to antibodies. In one experiment, engineered cells secrete a fluorescent marker protein alongside the antibody. This approach could eventually enable long-term delivery of missing enzymes for inherited disorders, hormones for metabolic diseases or protein-based cancer therapies.
The treatment also offers a level of control that simple infusions cannot match. The antibody supply rises after a vaccine boost and settles back down on its own. In theory, future versions could include an on-off switch that allows dialing production up or down as a patient’s needs change.
While the results in mice are promising, significant challenges remain before human application. Editing a patient's stem cells necessitates rigorous safety evaluation. Current protocols often require bone marrow conditioning with chemotherapy, which restricts eligibility.
Long-term safety also needs more study. The edited cells will live in the body for decades, and any rare side effect could take years to appear. Clear proof is needed that the editing tool lands only where it should and that the engineered cells do not turn harmful over time.
For a century, medicine has treated antibody therapy as something that comes in a vial. The vial empties, the drug fades and the patient comes back for more. This study sketches a different model. The vial becomes a one-time event. The body itself becomes the source of the medicine, ready to deliver it again whenever a simple vaccine signal calls for more.
That shift could change how the world treats some diseases, from HIV and flu to malaria and cancer. The work is still in animals, and many questions remain. Even so, the idea that a single treatment could provide years of protection, with a built-in way to top it off, points to a future where chronic infusions may no longer define what living with a long-term disease has to look like.
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。